Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Highly efficient and eco-innovative probiotic food supplement for antibiotic-associated disorders prevention

Obiettivo

Development of novel probiotic solutions for specific illnesses and health problems, ex: Obesity, Depression, Crohn or Colitis diseases.

The solutions proposed by MyBiotics will use Mycrobe TM a delivery technology to overpass the biologic barriers :gastric acid, pancreatic juice and bile salts, and deliver sufficient quantity of living probiotic directly to colonize the gastro intestinal tract were they are therapeutically efficient.

MyBiotics will design for each targeted disease a set of specific bacteria and validate their selection by using MycrobeTM as leverage to provide unreached comfort and easy variation during the selection and test of the probiotics.

The ambition is to provide pharmabiotic solutions for specific diseases and provide robust clinical results for lobbying activities with the EMA, EFSA and FDA for the regulation

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-SMEInst-2014-2015

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

MYBIOTICS PHARMA LTD
Contributo netto dell'UE
€ 50 000,00
Indirizzo
5 GOLDA MEIR BLVD, RTH FLOOR
7414001 Ness Ziona
Israele
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00